MSP Recoveryの空売り状況は、投資家がMSP Recoveryの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

MSP Recovery (NASDAQ:MSPR) 株価情報, 空売り情報

MSP Recovery

MSP Recovery Inc is a healthcare recovery and data analytics company. The business model includes two principal lines of business: Claims Recovery and Chase to Pay Services. It offers an antiquated healthcare reimbursement system with data-driven solutions to secure recoveries against responsible parties. MSP Recovery provides the healthcare industry with comprehensive compliance solutions platform to recover any claims where the law places primary payment responsibility on another payer.

MSP Recovery, Inc. - Class A Common Stock

MSP Recovery Inc

News

Citigroup Credit Card Delinquency Rate 1.44% At March End; Credit Card Charge-Offs 3.00% In March

Shares of Mural Oncology plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MURA#NASDAQ">MURA</a>) are soaring Monday following the company's announcement that it will discontinue clinical development of its lead drug candidate Nemvaleukin and begin <a href="https://www.benzinga.com/pressreleases/25/04/g44810459/mural-oncology-announces-plans-to-explore-strategic-alternatives">exploring strategic alternatives</a>.
What To Know: Mural Oncology announced that it&#8217;s discontinuing all clinical development of Nemvaleukin alfa and plans to immediately commence the exploration of strategic alternatives focused on maximizing shareholder value.
The decision follows a review of data from two clinical trials, ARTISTRY-6 in melanoma and ARTISTRY-7 in ovarian cancer, where the drug failed to demonstrate sufficient efficacy.
In response to the program's termination, Mural plans to reduce its workforce by approximately 90% and will now evaluate options that include a potential sale, merger, or other business combination. The company has retained Lucid Capital Markets as its financial advisor for the process.
Mural reported approximately $144.4 million in cash and equivalents, as of the end of 2024. While no potential buyers have come forward and discussions are not currently underway, Mural is now formally considered to be in an "offer period" under the Irish Takeover Rules, which apply due to the company&#8217;s legal structure.
<h3 class="wp-block-heading">How To Buy MURA Stock</h3>
By now you're likely curious about how to participate in the market for Mural Oncology &#8211; be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy &#8220;fractional shares,&#8221; which allows you to own portions of stock without buying an entire share.
In the case of Mural Oncology, which is trading at $2.59 as of publishing time, $100 would buy you 38.61 shares of stock.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to &#8220;go short&#8221; a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.
MURA Price Action: Mural Oncology shares were up 147.4% at $2.54 at the time of publication, according to<a href="https://pro.benzinga.com/dashboard?new_user=False&amp;backend=google-oauth2"> Benzinga Pro.</a>
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0415"><img loading="lazy" decoding="async" width="1024" height="532" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/15132427/Screenshot-2025-04-15-at-13.23.57-1024x532.png" alt="" class="wp-image-872685" style="width:399px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/15132427/Screenshot-2025-04-15-at-13.23.57-1024x532.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/15132427/Screenshot-2025-04-15-at-13.23.57-300x156.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/15132427/Screenshot-2025-04-15-at-13.23.57-768x399.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/15132427/Screenshot-2025-04-15-at-13.23.57-1536x799.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/15132427/Screenshot-2025-04-15-at-13.23.57.png 1912w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/04/44817677/citigroup-ceo-jane-fraser-bets-us-will-still-be-worlds-leading-economy-and-dollar-the-reserve-currency-after-trade-uncertainty-settles">Citigroup CEO Jane Fraser Bets US Will &#8216;Still Be World&#8217;s Leading Economy&#8217; And Dollar &#8216;The Reserve Currency&#8217; After Trade Uncertainty Settles</a></li>
</ul>
Image via Shutterstock.

Movers

MURA

Mural Oncology Shares Surge As Company Explores Strategic Alternatives: What's Going On?

Shares of Forge Global Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FRGE#NYSE">FRGE</a>) are trading higher Monday after the implementation of a 1-for-15 <a href="https://www.benzinga.com/quote/FRGE/news">reverse stock split.</a>
What To Know: The reverse split, which took effect on April 14 2025, was approved by shareholders at a special meeting held on March 27 and authorized by the company's board of directors on March 28.
The reverse stock split reduced the number of Forge's outstanding common shares, consolidating every fifteen existing shares into one. Trading on a split-adjusted basis began on April 15.
FRGE Price Action: Forge Global Holdings shares were up 23.3% at $11.88 at the time of writing, according to <a href="https://pro.benzinga.com/dashboard?new_user=False&amp;backend=google-oauth2">Benzinga Pro.</a>
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0415"><img loading="lazy" decoding="async" width="1024" height="540" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/15134004/Screenshot-2025-04-15-at-13.39.43-1024x540.png" alt="" class="wp-image-872718" style="width:451px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/15134004/Screenshot-2025-04-15-at-13.39.43-1024x540.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/15134004/Screenshot-2025-04-15-at-13.39.43-300x158.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/15134004/Screenshot-2025-04-15-at-13.39.43-768x405.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/15134004/Screenshot-2025-04-15-at-13.39.43-1536x810.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/15134004/Screenshot-2025-04-15-at-13.39.43.png 1911w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/04/44817677/citigroup-ceo-jane-fraser-bets-us-will-still-be-worlds-leading-economy-and-dollar-the-reserve-currency-after-trade-uncertainty-settles">Citigroup CEO Jane Fraser Bets US Will &#8216;Still Be World&#8217;s Leading Economy&#8217; And Dollar &#8216;The Reserve Currency&#8217; After Trade Uncertainty Settles</a></li>
</ul>
Image Via Shutterstock.

FRGE

Forge Global Shares Surge Following Reverse Stock Split Implementation

<a target="_blank" href="https://www.benzinga.com/quote/SNY" rel="noreferrer noopener">Sanofi SA</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>) on Tuesday shared progress from its mid- to <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">late-stage respiratory pipeline</a>.
The French drug maker <a href="https://www.sanofi.com/en/media-room/press-releases/2025/2025-04-15-05-00-00-3061368" target="_blank" rel="noreferrer noopener">reported</a> preliminary results from the TIDE-Asthma phase 2 study of amlitelimab and its efficacy in heterogeneous inflammatory asthma. Here&#8217;s what we know: 
<ul>
<li>The primary endpoint of the annualized exacerbation rate at week 48 was not met at the highest dose level, leading to nominal significance at the medium and low doses.</li>
<li>Treatment with amlitelimab led to nominally significant and clinically meaningful reductions in asthma exacerbations at the medium dose tested and a numerically greater reduction in exacerbations at the high dose at week 60.</li>
<li>A nominally significant and clinically meaningful improvement in secondary endpoints of lung function and asthma control was evident.</li>
<li>In a patient subgroup, amlitelimab showed nominally significant and clinically meaningful improvements in exacerbations (with a reduction of more than 70%), lung function, and asthma control at week 60.</li>
<li>The phase 3 program is currently being planned.</li>
<li>In the TIDE-Asthma study, patients were treated every four weeks for the first 24 weeks and every 12 weeks for the remaining 36 weeks. Amlitelimab&#8217;s durable efficacy through 60 weeks of treatment supports a quarterly maintenance dosing schedule.</li>
<li>The safety profile was consistent with previous studies across indications, with no new safety signals identified throughout the 60-week treatment period.</li>
</ul>
Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/44724763/pharma-industry-faces-jitters-as-trump-hints-at-historic-tariffs-bofa-outlines-probable-timeline" rel="noreferrer noopener">Pharma Industry Faces Jitters As Trump Hints At Historic Tariffs, BofA Outlines Probable Timeline</a>
Separately, Sanofi said lunsekimig is being explored in a broad population of asthma patients, regardless of their inflammation and severity status.
<ul>
<li>The readout of the AIRCULES phase 2 study in moderate to severe asthma is anticipated in 2026 </li>
<li>The AIRLYMPUS phase 2 study in high-risk asthma was initiated in Q4 2024.</li>
<li>The readout of the phase 2 study in patients with chronic rhinosinusitis with nasal polyps is anticipated in 2026.</li>
<li>A phase 2/3 study in chronic obstructive pulmonary disease (COPD) will begin in 2025.</li>
</ul>
In partnership with Regeneron Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>), two phase 3 studies were initiated so far this year.
Itepekimab is currently being explored in COPD in two phase 3 studies, AERIFY-1 and AERIFY-2, with the readout anticipated in H2 2025, and in one phase 2 study, AERIFY-3, with the readout anticipated in H2 2025.
Finally, itepekimab is being explored in a phase 2 study in bronchiectasis, with the readout anticipated in 2026.
In May 2024, Sanofi <a target="_blank" href="https://www.sanofi.com/en/media-room/press-releases/2024/2024-05-22-17-15-00-2886776?tblci=GiCUX7wvU_AgmIIiQduNYr6JQuJQLy6SZJGvpyeZuCzyqiCN1VcoxvTN4f7-y-PqATDviEo" rel="noreferrer noopener">reported</a> results from the Phase 2 study of oral&nbsp;rilzabrutinib&nbsp;in adult patients with uncontrolled moderate-to-severe asthma.
Two doses of&nbsp;rilzabrutinib, 800 mg daily and 1200 mg <a target="_blank" href="https://www.benzinga.com/news/24/05/38970663/first-advanced-oral-treatment-for-asthma-sanofis-investigational-drug-shows-potential" rel="noreferrer noopener">daily, were studied</a>.
The data showed that treatment with oral&nbsp;rilzabrutinib&nbsp;at both high and low doses led to a numerical reduction in loss of asthma control (LOAC) events (the primary endpoint) and improvements in symptoms in adult patients with uncontrolled moderate-to-severe asthma.&nbsp;
Price Action: SNY stock is down 1.33% at $51.15 at the last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/media/25/04/44819954/apple-plans-on-device-ai-data-analysis-to-boost-privacy-catch-up-in-ai-race" target="_blank" rel="noreferrer noopener">Apple Plans On-Device AI Data Analysis To Boost Privacy, Catch Up In AI Race</a></li>
</ul>
Image: Shutterstock

Biotech

Large Cap

Health Care

General

REGN

Sanofi Asthma Drug Misses Primary Goal, Plans For Pivotal Study

WIIM

Albemarle shares are trading lower after Baird and Citigroup cut their respective price targets on the stock.

Trump Media & Technology shares are trading higher after the company announced the launch of a suite of several separately managed accounts to offer thematic investment strategies to investors.

WARREN, N.J., April 15, 2025 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=Xrpp6xUQ3VjTK0m2mLnFbi4sIEGlj06OPCA-xdRA6D-xrxq2XZpHVr5Ymgs5f8EUc7vjOYHeizJR2-NDwGUTvw==">Tevogen</a> ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVGN#NASDAQ">TVGN</a>), today announced the commission of Databricks, Inc., a leader in data, analytics and artificial intelligence (AI), with an aim to accelerate the development of PredicTcell, the Company's proprietary AI-driven target prediction model for precision immunotherapy.&nbsp;
Databricks will provide a dedicated data engineering team and its expertise in building, scaling, and governing data and AI systems. This support should advance PredicTcell's capabilities in modeling immunologically active HLA+ peptide complexes and predicting T cell receptor (TCR) engagement with those complexes. The efforts will be directed to bring two foundational models to bear based on the company's revolutionary ExacTcell&#x2122;&nbsp;platform: predicting immunologically active peptides through machine learning and developing a predictive T cell receptor binding model.
This announcement marks the third foundational support pillar for Tevogen.AI, the Company's AI initiative which aims to transform precision medicine:
<ul>
<li>Microsoft Research&nbsp;– contributing digital infrastructure, scientific research, and AI expertise.</li>
<li>Databricks – data infrastructure, engineering, and analytics to enable AI model development.</li>
<li>Tevogen Bio – providing clinical and immunological science and strategic leadership.</li>
</ul>

TVGN

Tevogen Commissions Databricks To Accelerate Development Of PredicTcell, Ai-Driven Target Prediction Model For Precision Immunotherapy

TTAN

ServiceTitan shares are trading higher after the company announced a strategic partnership with Cobalt Service Partners to power 12 commercial access solutions brands with its business management software.

Boeing Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>) shares are trading lower Tuesday following reports that China has halted <a href="https://www.benzinga.com/economics/macro-economic-events/25/04/44807285/bloomberg-reported-earlier-china-orders-halts-to-boeing-jet-deliveries">Boeing jet deliveries</a>.
What To Know: According to a Bloomberg <a href="https://www.bloomberg.com/news/articles/2025-04-15/china-tells-airlines-stop-taking-boeing-jets-as-trump-tariffs-expand-trade-war?embedded-checkout=true">report</a>, China has ordered its airline companies to stop taking deliveries of Boeing jets as the U.S.-China trade war intensifies.
People familiar with the matter reportedly said China also asked its airlines to refrain from purchasing any aircraft-related parts and equipment from U.S.-based companies.
The move comes in response to U.S. President Donald Trump&#8217;s reciprocal tariffs. While Trump has announced a temporary pause on tariffs for a majority of countries, he has continued to <a href="https://www.benzinga.com/government/regulations/25/04/44740040/chinas-growth-outlook-dims-as-trumps-125-tariffs-put-millions-of-jobs-at-risk-goldman-warns">ramp up pressure</a> on China.
The latest move from China also comes after China slapped 125% retaliatory tariffs on American goods over the weekend. Those tariffs alone would have more than doubled the cost of Boeing jets and other aircraft parts. 
See Also: <a href="https://www.benzinga.com/government/regulations/25/04/44812727/bessent-says-tariffs-on-china-are-far-from-a-joke-dismisses-treasury-dumping-fears">Bessent Says Tariffs On China Are &#8216;Far From A Joke,&#8217; Dismisses Treasury Dumping Fears</a>
Bloomberg further reported that the Chinese government is mulling ways to provide assistance to its airlines that have current jet leases with Boeing and are now battling higher costs. 
Boeing reportedly has about 10 737 Max aircraft ready for deliveries to Chinese airlines. The report indicates that some of the jets are stationed by Boeing&#8217;s Seattle factory, while others are sitting at a finishing location in Zhoushan, China.
BA Price Action: <a href="http://benzinga.com/quote/ba">Boeing shares</a> fell as much as 2.5% on Tuesday, before finding some support. The stock was down 1.55% at $156.81 at the time of publication Tuesday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: courtesy of Boeing.

Boeing Stock Is Sliding Tuesday: What's Going On?

Investors with a lot of money to spend have taken a bullish stance on Unity Software (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/U#NYSE">U</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with U, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://www.benzinga.com/pro/">Benzinga</a>'s options scanner spotted 9 uncommon options trades for Unity Software.
This isn't normal.
The overall sentiment of these big-money traders is split between 55% bullish and 44%, bearish.
Out of all of the special options we uncovered, 5 are puts, for a total amount of $326,473, and 4 are calls, for a total amount of $146,450.
<h3>Predicted Price Range</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $17.0 and $28.0 for Unity Software, spanning the last three months.
<h3>Volume &amp; Open Interest Trends</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Unity Software's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Unity Software's significant trades, within a strike price range of $17.0 to $28.0, over the past month.
<h3>Unity Software Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1744740091_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>U</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$1.44</td>
<td>$1.34</td>
<td>$1.35</td>
<td>$18.00</td>
<td>$148.5K</td>
<td>1.2K</td>
<td>1.5K</td>
</tr>
<tr>
<td>U</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$11.4</td>
<td>$10.5</td>
<td>$10.5</td>
<td>$28.00</td>
<td>$75.6K</td>
<td>2.9K</td>
<td>100</td>
</tr>
<tr>
<td>U</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$4.05</td>
<td>$3.9</td>
<td>$4.05</td>
<td>$18.00</td>
<td>$46.5K</td>
<td>221</td>
<td>115</td>
</tr>
<tr>
<td>U</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$1.25</td>
<td>$1.23</td>
<td>$1.24</td>
<td>$20.00</td>
<td>$43.4K</td>
<td>4.0K</td>
<td>835</td>
</tr>
<tr>
<td>U</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$3.1</td>
<td>$3.05</td>
<td>$3.05</td>
<td>$20.00</td>
<td>$42.1K</td>
<td>3.6K</td>
<td>146</td>
</tr>
</tbody>
</table>

<h3>About Unity Software</h3>
Unity Software Inc provides a software platform for creating and operating interactive, real-time 3D content. The platform can be used to create, run, and monetize interactive, real-time 2D and 3D content for mobile phones, tablets, PCs, consoles, and augmented and virtual reality devices. The business is spread across the United States, Greater China, EMEA, APAC, and other Americas, and key revenue is derived from the EMEA region. The products are used in the gaming industry, retail, automotive, architecture, engineering, and construction.
After a thorough review of the options trading surrounding Unity Software, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Unity Software's Current Market Status</h3>
<ul>
<li>Currently trading with a volume of 3,350,130, the U's price is up by 2.97%, now at $18.7. </li>
<li>RSI readings suggest the stock is currently is currently neutral between overbought and oversold.</li>
<li>Anticipated earnings release is in 23 days.</li>
</ul>
<h3>Expert Opinions on Unity Software</h3>
Over the past month, 4 industry analysts have shared their insights on this stock, proposing an average target price of $20.25.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from Jefferies continues to hold a Hold rating for Unity Software, targeting a price of $24. 
&#x2A; An analyst from UBS has decided to maintain their Neutral rating on Unity Software, which currently sits at a price target of $22. 
&#x2A; An analyst from Wells Fargo persists with their Equal-Weight rating on Unity Software, maintaining a target price of $19. 
&#x2A; Maintaining their stance, an analyst from Jefferies continues to hold a Hold rating for Unity Software, targeting a price of $16. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Unity Software, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.

Options

Markets

Check Out What Whales Are Doing With Unity Software

Deep-pocketed investors have adopted a bullish approach towards Rivian Automotive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in RIVN usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 21 extraordinary options activities for Rivian Automotive. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 52% leaning bullish and 42% bearish. Among these notable options, 11 are puts, totaling $475,084, and 10 are calls, amounting to $460,065.
<h3>Projected Price Targets</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $9.0 to $15.0 for Rivian Automotive during the past quarter. 
<h3>Insights into Volume &amp; Open Interest</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Rivian Automotive's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Rivian Automotive's substantial trades, within a strike price spectrum from $9.0 to $15.0 over the preceding 30 days.
<h3>Rivian Automotive Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1744740086_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>RIVN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$4.55</td>
<td>$4.5</td>
<td>$4.55</td>
<td>$15.00</td>
<td>$122.3K</td>
<td>40.5K</td>
<td>361</td>
</tr>
<tr>
<td>RIVN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$3.3</td>
<td>$3.25</td>
<td>$3.3</td>
<td>$10.00</td>
<td>$99.0K</td>
<td>4.5K</td>
<td>300</td>
</tr>
<tr>
<td>RIVN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>06/20/25</td>
<td>$0.69</td>
<td>$0.66</td>
<td>$0.69</td>
<td>$14.00</td>
<td>$98.3K</td>
<td>15.0K</td>
<td>1.6K</td>
</tr>
<tr>
<td>RIVN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$1.57</td>
<td>$1.56</td>
<td>$1.57</td>
<td>$11.00</td>
<td>$62.1K</td>
<td>3.8K</td>
<td>412</td>
</tr>
<tr>
<td>RIVN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$1.69</td>
<td>$1.67</td>
<td>$1.69</td>
<td>$12.50</td>
<td>$55.6K</td>
<td>39.0K</td>
<td>330</td>
</tr>
</tbody>
</table>

<h3>About Rivian Automotive</h3>
Rivian Automotive Inc is an automotive manufacturer that develops and builds electric vehicles ("EVs") as well as software and services. It launches its consumer vehicle business with the R1 platform consisting of two vehicles: the R1T, and the R1S. The company has two reportable segments: Automotive, which derives the majority of revenue, and Software and Services segment. The Automotive reportable segment derives its revenues and cost of revenues from the production and sale of new EVs and the sale of regulatory credits generated by the production and sale of EVs. The Software and services reportable segment derives its revenues and cost of revenues primarily from remarketing, vehicle repair and maintenance services, and vehicle electrical architecture and software development services.
After a thorough review of the options trading surrounding Rivian Automotive, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Present Market Standing of Rivian Automotive</h3>
<ul>
<li>With a trading volume of 9,059,763, the price of RIVN is down by -1.5%, reaching $11.85.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 21 days from now.</li>
</ul>
<h3>What Analysts Are Saying About Rivian Automotive</h3>
In the last month, 5 experts released ratings on this stock with an average target price of $12.4.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from Mizuho continues to hold a Neutral rating for Rivian Automotive, targeting a price of $11. 
&#x2A; Consistent in their evaluation, an analyst from UBS keeps a Neutral rating on Rivian Automotive with a target price of $12. 
&#x2A; An analyst from Piper Sandler has revised its rating downward to Neutral, adjusting the price target to $13. 
&#x2A; An analyst from Goldman Sachs has decided to maintain their Neutral rating on Rivian Automotive, which currently sits at a price target of $12. 
&#x2A; An analyst from Baird has decided to maintain their Neutral rating on Rivian Automotive, which currently sits at a price target of $14. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Rivian Automotive options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.

RIVN

Rivian Automotive's Options: A Look at What the Big Money is Thinking

Microsoft Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) has <a href="https://www.prnewswire.com/news-releases/fidelis-atmosclear-signs-agreement-with-microsoft-for-high-quality-carbon-removal-from-project-in-louisiana-302428324.html">agreed to purchase 6.75 million metric tons</a> of engineered carbon removals over the next 15 years through a new partnership with AtmosClear BR, LLC, a portfolio company of Fidelis. 
The agreement represents the most substantial deal for permanent carbon removal ever signed.
The initiative leverages bioenergy with carbon capture and storage (BECCS) technology and is tied to a major carbon capture project planned for Louisiana. 
&#8220;This contract with Microsoft marks a transformative moment for the high-quality, engineered carbon removal market,&#8221; said Fidelis CEO Daniel J. Shapiro.
Also Read: <a href="https://www.benzinga.com/25/04/44799936/nvidia-to-build-500b-ai-infrastructure-in-us-in-the-next-four-years-details">Nvidia To Build $500 Billion AI Infrastructure In US In the Next Four Years</a>
AtmosClear intends to construct a BECCS facility at the Port of Greater Baton Rouge. The facility will generate clean energy by processing renewable materials such as sugarcane residue and forest trimmings.
The site is expected to sequester approximately 680,000 metric tons of biogenic carbon dioxide annually. The captured carbon will either be stored underground or repurposed into low-carbon fuel and feedstocks.
Construction is anticipated to begin in 2026, with commercial activity targeted for 2029. The project will funnel over $800 million in financing and is projected to produce around 600 construction roles and 75 permanent jobs.
&#8220;We are proud to work with Fidelis on this pathbreaking project, which will bring together science, engineering, and commercial innovations to offer a compelling model for carbon removal in the United States,&#8221; said Brian Marrs, senior director of Energy &amp; Carbon Removal at Microsoft. 
It is also expected to revitalize forest management employment, which has been negatively affected by recent mill shutdowns in the area.
The deal supports Microsoft&#8217;s aim to be carbon-negative by 2030, reducing the company&#8217;s greenhouse gas (GHG) emissions by more than half and removing the rest.
Price Action: MSFT shares traded higher by 0.26% at $388.80 in premarket at last check Tuesday.
Read Next: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/04/44800444/goldman-sachs-cuts-outlook-for-these-hotel-and-lodging-stocks-as-potential-recession-looms">Goldman Sachs Cuts Outlook For These Hotel And Lodging Stocks As Potential Recession Looms</a>
Photo: Shutterstock

MSFT

Microsoft To Back World's Largest CO2 Removal Project Worth About $800 Million

Whales with a lot of money to spend have taken a noticeably bullish stance on Delta Air Lines.
Looking at options history for Delta Air Lines (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAL#NYSE">DAL</a>) we detected 15 trades.
If we consider the specifics of each trade, it is accurate to state that 53% of the investors opened trades with bullish expectations and 26% with bearish.
From the overall spotted trades, 8 are puts, for a total amount of $790,771 and 7, calls, for a total amount of $435,680.
<h3>Projected Price Targets</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $37.0 to $55.0 for Delta Air Lines during the past quarter. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Delta Air Lines's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Delta Air Lines's whale activity within a strike price range from $37.0 to $55.0 in the last 30 days. 
<h3>Delta Air Lines 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1744740080_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>DAL</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$6.8</td>
<td>$6.75</td>
<td>$6.8</td>
<td>$42.00</td>
<td>$342.9K</td>
<td>4.0K</td>
<td align="right">376</td>
</tr>
<tr>
<td>DAL</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>05/16/25</td>
<td>$2.04</td>
<td>$1.99</td>
<td>$2.04</td>
<td>$40.00</td>
<td>$137.3K</td>
<td>9.9K</td>
<td align="right">694</td>
</tr>
<tr>
<td>DAL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$7.05</td>
<td>$6.4</td>
<td>$6.85</td>
<td>$42.00</td>
<td>$124.6K</td>
<td>1.2K</td>
<td align="right">202</td>
</tr>
<tr>
<td>DAL</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>04/25/25</td>
<td>$1.52</td>
<td>$1.24</td>
<td>$1.52</td>
<td>$41.00</td>
<td>$121.6K</td>
<td>263</td>
<td align="right">801</td>
</tr>
<tr>
<td>DAL</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$3.1</td>
<td>$3.0</td>
<td>$3.15</td>
<td>$42.00</td>
<td>$100.8K</td>
<td>2.4K</td>
<td align="right">321</td>
</tr>
</tbody>
</table>

<h3>About Delta Air Lines</h3>
Atlanta-based Delta Air Lines is one of the world's largest airlines, with a network of over 300 destinations in more than 50 countries. Delta operates a hub-and-spoke network, where it gathers and distributes passengers across the globe through its biggest hubs in Atlanta, New York, Salt Lake City, Detroit, Seattle, and Minneapolis-St. Paul. Delta has historically earned most of its international revenue and profits from flying passengers over the Atlantic Ocean.
After a thorough review of the options trading surrounding Delta Air Lines, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Delta Air Lines's Current Market Status</h3>
<ul>
<li>With a trading volume of 5,036,871, the price of DAL is up by 2.36%, reaching $41.25.</li>
<li>Current RSI values indicate that the stock is is currently neutral between overbought and oversold.</li>
<li>Next earnings report is scheduled for 86 days from now.</li>
</ul>
<h3>What Analysts Are Saying About Delta Air Lines</h3>
A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $51.2.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; In a cautious move, an analyst from Jefferies downgraded its rating to Hold, setting a price target of $46. 
&#x2A; Maintaining their stance, an analyst from Raymond James continues to hold a Strong Buy rating for Delta Air Lines, targeting a price of $62. 
&#x2A; An analyst from B of A Securities has decided to maintain their Buy rating on Delta Air Lines, which currently sits at a price target of $56. 
&#x2A; Reflecting concerns, an analyst from UBS lowers its rating to Neutral with a new price target of $42. 
&#x2A; Maintaining their stance, an analyst from Susquehanna continues to hold a Positive rating for Delta Air Lines, targeting a price of $50. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Delta Air Lines options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.

Spotlight on Delta Air Lines: Analyzing the Surge in Options Activity

10 analysts have shared their evaluations of Terreno Realty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRNO#NYSE">TRNO</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">7</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $67.4, a high estimate of $78.00, and a low estimate of $57.00. A decline of 2.01% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2025/1744740061_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The standing of Terreno Realty among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;-----------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Alexander Goldfarb &#x7C;Piper Sandler &#x7C;Lowers &#x7C;Neutral &#x7C; $60.00&#x7C;$61.00 &#x7C; 
&#x7C;Greg McGinniss &#x7C;Scotiabank &#x7C;Lowers &#x7C;Sector Perform &#x7C; $57.00&#x7C;$68.00 &#x7C; 
&#x7C;Alexander Goldfarb &#x7C;Piper Sandler &#x7C;Lowers &#x7C;Neutral &#x7C; $61.00&#x7C;$78.00 &#x7C; 
&#x7C;Brendan Lynch &#x7C;Barclays &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $57.00&#x7C;$60.00 &#x7C; 
&#x7C;Greg McGinniss &#x7C;Scotiabank &#x7C;Raises &#x7C;Sector Perform &#x7C; $68.00&#x7C;$64.00 &#x7C; 
&#x7C;Caitlin Burrows &#x7C;Goldman Sachs &#x7C;Raises &#x7C;Buy &#x7C; $77.00&#x7C;$65.00 &#x7C; 
&#x7C;John Kim &#x7C;BMO Capital &#x7C;Raises &#x7C;Market Perform &#x7C; $73.00&#x7C;$71.00 &#x7C; 
&#x7C;Mitch Germain &#x7C;JMP Securities &#x7C;Maintains &#x7C;Market Outperform&#x7C; $72.00&#x7C;$72.00 &#x7C; 
&#x7C;Alexander Goldfarb &#x7C;Piper Sandler &#x7C;Lowers &#x7C;Overweight &#x7C; $78.00&#x7C;$80.00 &#x7C; 
&#x7C;John Kim &#x7C;BMO Capital &#x7C;Announces &#x7C;Market Perform &#x7C; $71.00&#x7C;- &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Terreno Realty. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Terreno Realty compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Terreno Realty's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Terreno Realty's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/TRNO/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Terreno Realty analyst ratings.</a>
<h2>About Terreno Realty</h2>
Terreno Realty Corp is a real estate investment trust engaged in acquiring, owning, and operating industrial real estate in six coastal U.S. markets: Los Angeles, Northern New Jersey/New York City, San Francisco Bay Area, Seattle, Miami, and Washington, D.C. The company invests in several types of industrial real estate, including warehouse/distribution, flex (including light industrial and research and development), transshipment, and improved land.
<h3>A Deep Dive into Terreno Realty's Financials</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Terreno Realty's revenue growth over a period of 3M has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately 19.92%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Real Estate sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Terreno Realty's net margin excels beyond industry benchmarks, reaching 73.07%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Terreno Realty's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 2.08%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Terreno Realty's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 1.62%, the company showcases efficient use of assets and strong financial health.
Debt Management: Terreno Realty's debt-to-equity ratio is below the industry average. With a ratio of 0.22, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>Analyst Ratings: What Are They?</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

TRNO

Expert Outlook: Terreno Realty Through The Eyes Of 10 Analysts

In the last three months, 5 analysts have published ratings on Lands' End (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LE#NASDAQ">LE</a>), offering a diverse range of perspectives from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $20.0, along with a high estimate of $20.00 and a low estimate of $20.00. Holding firm without variation, the current average remains at the previous average price target. 
<img src="https://www.benzinga.com/files/images/story/2025/1744740054_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
A clear picture of Lands' End's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;---------------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Eric Beder &#x7C;Small Cap Consumer Research&#x7C;Maintains &#x7C;Buy &#x7C; $20.00&#x7C;$20.00 &#x7C; 
&#x7C;Eric Beder &#x7C;Small Cap Consumer Research&#x7C;Maintains &#x7C;Buy &#x7C; $20.00&#x7C;$20.00 &#x7C; 
&#x7C;Eric Beder &#x7C;Small Cap Consumer Research&#x7C;Maintains &#x7C;Buy &#x7C; $20.00&#x7C;$20.00 &#x7C; 
&#x7C;Eric Beder &#x7C;Small Cap Consumer Research&#x7C;Maintains &#x7C;Buy &#x7C; $20.00&#x7C;$20.00 &#x7C; 
&#x7C;Eric Beder &#x7C;Small Cap Consumer Research&#x7C;Maintains &#x7C;Buy &#x7C; $20.00&#x7C;$20.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Lands' End. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Lands' End compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Lands' End's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Capture valuable insights into Lands' End's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/LE/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Lands' End analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>About Lands' End</h2>
Lands' End Inc is a United States-based multi-channel retailer of casual clothing, accessories, and footwear, as well as home products. The company's operating segment includes U.S. eCommerce; International; Outfitters; Third Party and Retail. It generates maximum revenue from the U.S. eCommerce segment. The U.S. eCommerce segment offers products through the company's eCommerce website. Geographically operates in USA, Europe, Asia, it derives a majority of its revenue from the United States.
<h3>Lands' End: A Financial Overview</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Challenges: Lands' End's revenue growth over 3M faced difficulties. As of 31 January, 2025, the company experienced a decline of approximately -14.22%. This indicates a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Consumer Discretionary sector.
Net Margin: Lands' End's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 4.19% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Lands' End's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 8.0% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Lands' End's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 2.3% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: With a below-average debt-to-equity ratio of 1.1, Lands' End adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Analyst Ratings: What Are They?</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What Analysts Are Saying About Lands' End Stock

Providing a diverse range of perspectives from bullish to bearish, 10 analysts have published ratings on Applied Mat (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMAT#NASDAQ">AMAT</a>) in the last three months.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">6</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Applied Mat, presenting an average target of $197.2, a high estimate of $235.00, and a low estimate of $165.00. A 5.9% drop is evident in the current average compared to the previous average price target of $209.56. 
<img src="https://www.benzinga.com/files/images/story/2025/1744740044_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The standing of Applied Mat among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Brian Chin &#x7C;Stifel &#x7C;Lowers &#x7C;Buy &#x7C; $195.00&#x7C;$235.00 &#x7C; 
&#x7C;Atif Malik &#x7C;Citigroup &#x7C;Lowers &#x7C;Buy &#x7C; $170.00&#x7C;$202.00 &#x7C; 
&#x7C;Blayne Curtis &#x7C;Jefferies &#x7C;Announces &#x7C;Buy &#x7C; $195.00&#x7C;- &#x7C; 
&#x7C;Atif Malik &#x7C;Citigroup &#x7C;Raises &#x7C;Buy &#x7C; $202.00&#x7C;$194.00 &#x7C; 
&#x7C;Charles Shi &#x7C;Needham &#x7C;Lowers &#x7C;Buy &#x7C; $195.00&#x7C;$200.00 &#x7C; 
&#x7C;Tom O'Malley &#x7C;Barclays &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $190.00&#x7C;$200.00 &#x7C; 
&#x7C;Brian Chin &#x7C;Stifel &#x7C;Lowers &#x7C;Buy &#x7C; $235.00&#x7C;$250.00 &#x7C; 
&#x7C;Mehdi Hosseini &#x7C;Susquehanna &#x7C;Raises &#x7C;Neutral &#x7C; $165.00&#x7C;$155.00 &#x7C; 
&#x7C;Steve Barger &#x7C;Keybanc &#x7C;Maintains &#x7C;Overweight &#x7C; $225.00&#x7C;$225.00 &#x7C; 
&#x7C;Tom O'Malley &#x7C;Barclays &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $200.00&#x7C;$225.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Applied Mat. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Applied Mat compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Applied Mat's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Applied Mat's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/AMAT/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Applied Mat analyst ratings.</a>
<h2>Get to Know Applied Mat Better</h2>
Applied Materials Inc is the largest semiconductor wafer fabrication equipment, or WFE, manufacturer in the world. Applied Materials has a broad portfolio spanning nearly every corner of the WFE ecosystem. Specifically, Applied Materials holds a market share leadership position in deposition, which entails the layering of new materials on semiconductor wafers. It is more exposed to general-purpose logic chips made at integrated device manufacturers and foundries. It counts the largest chipmakers in the world as customers, including TSMC, Intel, and Samsung.
<h3>Applied Mat: A Financial Overview</h3>
Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.
Positive Revenue Trend: Examining Applied Mat's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 6.84% as of 31 January, 2025, showcasing a substantial increase in top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Information Technology sector.
Net Margin: Applied Mat's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 16.54%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Applied Mat's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 6.3%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Applied Mat's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 3.5% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: With a below-average debt-to-equity ratio of 0.35, Applied Mat adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>The Significance of Analyst Ratings Explained</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AMAT

Analyst Expectations For Applied Mat's Future

29 analysts have expressed a variety of opinions on HubSpot (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUBS#NYSE">HUBS</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">9</td>
<td align="right">15</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">7</td>
<td align="right">11</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $838.38, with a high estimate of $980.00 and a low estimate of $675.00. Surpassing the previous average price target of $775.52, the current average has increased by 8.11%.
<img src="https://www.benzinga.com/files/images/story/2025/1744740036_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
A comprehensive examination of how financial experts perceive HubSpot is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;-----------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Samad Samana &#x7C;Jefferies &#x7C;Lowers &#x7C;Buy &#x7C; $700.00&#x7C;$900.00 &#x7C; 
&#x7C;Siti Panigrahi &#x7C;Mizuho &#x7C;Lowers &#x7C;Outperform &#x7C; $700.00&#x7C;$900.00 &#x7C; 
&#x7C;Taylor McGinnis &#x7C;UBS &#x7C;Lowers &#x7C;Buy &#x7C; $675.00&#x7C;$775.00 &#x7C; 
&#x7C;Steve Koenig &#x7C;Macquarie &#x7C;Announces &#x7C;Outperform &#x7C; $730.00&#x7C;- &#x7C; 
&#x7C;Firoz Valliji &#x7C;Bernstein &#x7C;Announces &#x7C;Market Perform &#x7C; $693.00&#x7C;- &#x7C; 
&#x7C;Brett Huff &#x7C;Stephens &amp; Co. &#x7C;Announces &#x7C;Overweight &#x7C; $769.00&#x7C;- &#x7C; 
&#x7C;Ryan Macwilliams &#x7C;Barclays &#x7C;Maintains &#x7C;Overweight &#x7C; $815.00&#x7C;$815.00 &#x7C; 
&#x7C;Nick Altmann &#x7C;Scotiabank &#x7C;Raises &#x7C;Sector Outperform&#x7C; $900.00&#x7C;$825.00 &#x7C; 
&#x7C;Keith Bachman &#x7C;BMO Capital &#x7C;Raises &#x7C;Outperform &#x7C; $885.00&#x7C;$690.00 &#x7C; 
&#x7C;Brian Peterson &#x7C;Raymond James &#x7C;Raises &#x7C;Outperform &#x7C; $980.00&#x7C;$750.00 &#x7C; 
&#x7C;Gabriela Borges &#x7C;Goldman Sachs &#x7C;Raises &#x7C;Buy &#x7C; $900.00&#x7C;$783.00 &#x7C; 
&#x7C;Rishi Jaluria &#x7C;RBC Capital &#x7C;Raises &#x7C;Outperform &#x7C; $950.00&#x7C;$825.00 &#x7C; 
&#x7C;Ken Wong &#x7C;Oppenheimer &#x7C;Raises &#x7C;Outperform &#x7C; $900.00&#x7C;$850.00 &#x7C; 
&#x7C;Mark Murphy &#x7C;JP Morgan &#x7C;Raises &#x7C;Overweight &#x7C; $850.00&#x7C;$725.00 &#x7C; 
&#x7C;Jackson Ader &#x7C;Keybanc &#x7C;Announces &#x7C;Overweight &#x7C; $920.00&#x7C;- &#x7C; 
&#x7C;Michael Turrin &#x7C;Wells Fargo &#x7C;Raises &#x7C;Overweight &#x7C; $940.00&#x7C;$835.00 &#x7C; 
&#x7C;Parker Lane &#x7C;Stifel &#x7C;Raises &#x7C;Buy &#x7C; $925.00&#x7C;$880.00 &#x7C; 
&#x7C;Taylor McGinnis &#x7C;UBS &#x7C;Raises &#x7C;Neutral &#x7C; $775.00&#x7C;$740.00 &#x7C; 
&#x7C;Terry Tillman &#x7C;Truist Securities &#x7C;Raises &#x7C;Buy &#x7C; $900.00&#x7C;$750.00 &#x7C; 
&#x7C;Joshua Reilly &#x7C;Needham &#x7C;Raises &#x7C;Buy &#x7C; $900.00&#x7C;$730.00 &#x7C; 
&#x7C;Ryan Macwilliams &#x7C;Barclays &#x7C;Raises &#x7C;Equal-Weight &#x7C; $815.00&#x7C;$725.00 &#x7C; 
&#x7C;Keith Weiss &#x7C;Morgan Stanley &#x7C;Raises &#x7C;Overweight &#x7C; $898.00&#x7C;$835.00 &#x7C; 
&#x7C;David Hynes &#x7C;Canaccord Genuity &#x7C;Raises &#x7C;Buy &#x7C; $900.00&#x7C;$710.00 &#x7C; 
&#x7C;Brent Bracelin &#x7C;Piper Sandler &#x7C;Raises &#x7C;Neutral &#x7C; $808.00&#x7C;$640.00 &#x7C; 
&#x7C;Mark Murphy &#x7C;JP Morgan &#x7C;Raises &#x7C;Overweight &#x7C; $725.00&#x7C;$635.00 &#x7C; 
&#x7C;Drew Foster &#x7C;Citigroup &#x7C;Raises &#x7C;Buy &#x7C; $900.00&#x7C;$750.00 &#x7C; 
&#x7C;Michael Turrin &#x7C;Wells Fargo &#x7C;Raises &#x7C;Overweight &#x7C; $835.00&#x7C;$810.00 &#x7C; 
&#x7C;Samad Samana &#x7C;Jefferies &#x7C;Raises &#x7C;Buy &#x7C; $900.00&#x7C;$860.00 &#x7C; 
&#x7C;Ryan Macwilliams &#x7C;Barclays &#x7C;Raises &#x7C;Equal-Weight &#x7C; $725.00&#x7C;$650.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to HubSpot. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of HubSpot compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of HubSpot's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into HubSpot's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/HUBS/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on HubSpot analyst ratings.</a>
<h2>Discovering HubSpot: A Closer Look</h2>
HubSpot provides a cloud-based marketing, sales, and customer service software platform referred to as the growth platform. The applications are available ala carte or packaged together. HubSpot's mission is to help companies grow better and has expanded from its initial focus on inbound marketing to embrace marketing, sales, and service more broadly. The company was founded in 2006, completed its initial public offering in 2014, and is headquartered in Cambridge, Massachusetts.
<h3>HubSpot: Delving into Financials</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: HubSpot displayed positive results in 3M. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately 20.84%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Information Technology sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: HubSpot's net margin excels beyond industry benchmarks, reaching 0.71%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of 0.27%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): HubSpot's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of 0.14%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: HubSpot's debt-to-equity ratio is below the industry average. With a ratio of 0.39, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>Analyst Ratings: What Are They?</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

HUBS

Forecasting The Future: 29 Analyst Projections For HubSpot

Builders FirstSource's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLDR#NYSE">BLDR</a>) short percent of float has fallen 14.68% since its last report. The company recently reported that it has 4.20 million shares sold short, which is 5.0% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.77 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Builders FirstSource Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1744740035_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Builders FirstSource has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Builders FirstSource's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Builders FirstSource's peer group average for short interest as a percentage of float is 4.27%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

BLDR

Is the Market Bullish or Bearish on Builders FirstSource?

Reliance's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RS#NYSE">RS</a>) short percent of float has fallen 43.75% since its last report. The company recently reported that it has 776 thousand shares sold short, which is 1.98% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.21 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Reliance Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1744740029_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Reliance has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Reliance's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Reliance's peer group average for short interest as a percentage of float is 5.73%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Is Reliance Gaining or Losing Market Support?

In the last three months, 5 analysts have published ratings on Agilon Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AGL#NYSE">AGL</a>), offering a diverse range of perspectives from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $5.2, along with a high estimate of $8.50 and a low estimate of $3.00. Observing a 46.07% increase, the current average has risen from the previous average price target of $3.56. 
<img src="https://www.benzinga.com/files/images/story/2025/1744740028_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The standing of Agilon Health among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Ryan Langston &#x7C;TD Cowen &#x7C;Raises &#x7C;Hold &#x7C; $6.00&#x7C;$3.50 &#x7C; 
&#x7C;Michael Halloran &#x7C;Baird &#x7C;Lowers &#x7C;Neutral &#x7C; $5.00&#x7C;$6.00 &#x7C; 
&#x7C;Amir Farahan &#x7C;Bernstein &#x7C;Raises &#x7C;Outperform &#x7C; $8.50&#x7C;$3.30 &#x7C; 
&#x7C;Sean Dodge &#x7C;RBC Capital &#x7C;Raises &#x7C;Outperform &#x7C; $3.50&#x7C;$3.00 &#x7C; 
&#x7C;Craig Jones &#x7C;Stifel &#x7C;Raises &#x7C;Hold &#x7C; $3.00&#x7C;$2.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Agilon Health. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Agilon Health compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Agilon Health's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Agilon Health's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/AGL/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Agilon Health analyst ratings.</a>
<h2>Get to Know Agilon Health Better</h2>
Agilon Health Inc is transforming healthcare by empowering primary care physicians for the health of the patients. The company enables physicians to create their own Medicare-centric globally capitated line of business. The company derives its revenue from Medical services.
<h3>Key Indicators: Agilon Health's Financial Health</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Agilon Health displayed positive results in 3M. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately 44.16%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Agilon Health's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -6.95%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Agilon Health's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -20.23%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Agilon Health's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -5.53%, the company may face hurdles in achieving optimal financial performance.
Debt Management: Agilon Health's debt-to-equity ratio is below the industry average at 0.09, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>The Basics of Analyst Ratings</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Where Agilon Health Stands With Analysts

Financing

Legal

Press Releases

MSP Recovery Announces Strategic Term Sheet Providing Prospective Liquidity and Restructuring of Existing Agreements to Remove Corporate Guaranteed Debt by over $1.2 Billion as Well as New Agreements Aimed at Driving Future Growth

MSPR

American Shared Hospital Services Common Stock

American Shared Hospital

Basel Medical Group Ltd - ordinary shares

Basel Medical Group

Cryo-Cell International, Inc. Common Stock

Cryo-Cell International

Enzo Biochem, Inc. Common Stock ($0.01 Par Value)

Enzo Biochem

Kindly MD

Mobile-health Network Solutions - Class A Ordinary Shares

Mobile-health Network

ModivCare

NewGenIvf Group Limited - Class A Ordinary Shares

NewGenIvf Group

Ontrak

P3 Health Partners Inc. - Class A Common Stock

P3 Health Partners

Prenetics Global Limited - Class A Ordinary Share

Comments

MSP Recovery

空売り

MSP Recovery (NASDAQ:MSPR) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル